GH-axis restoration in adults
Khorram 1997 ran a 16-week placebo-controlled trial of nightly subcutaneous GHRH(1-29) in age-advanced men and women that produced significant increases in nocturnal GH, IGF-1, IGFBP-3, skin thickness, and (in men) lean body mass. Sermorelin was FDA-approved for pediatric GH deficiency from 1997 to 2008 — the only peptide GH secretagogue ever cleared by the FDA — before being voluntarily withdrawn for commercial reasons, not safety concerns.
8 human studies · 6 animal studies
Key findings & citations
- Khorram 1997: significant increase in 12-hour integrated nocturnal GH, IGF-1, and skin thickness over 16 weeks.
- Vittone 1997 (older men): IGF-1 elevated by 2 weeks, lean body mass +1.26 kg, improved insulin sensitivity.
- Pediatric Geref formulation FDA-approved 1997-2008 for childhood GHD.
- Effect attenuates over time — endogenous somatotrope reserve sets a ceiling no GHRH analog can exceed.
Our take
The most established GH secretagogue. Modest, real, ceiling-limited — not a replacement for therapeutic-dose hGH, but the safest entry to the GH axis.